Gland Pharma Share Price Target 2025, 2026, 2027, 2028, 2030

Gland Pharma Share Price Target 2025, 2026, 2027, 2028, 2030:- The company was incorporated in 1956 in Hyderabad as a limited company, Gland Pharma, and received a certificate of incorporation from the Registrar of Companies in Hyderabad, Andhra Pradesh.

Therefore, in this article, we attempt to provide a fresh perspective on Gland Pharma shares through technical and fundamental analysis.

Gland Pharma Share Price Target 2025

In 1994, the company’s name was changed to Gland Pharma through a special resolution passed by the company’s shareholders, and as a result of this change, a new Memorandum of Association was issued by the Registrar of Companies in Hyderabad, Andhra Pradesh in 1995. It transitioned into a limited company in 1956. From 2014 to 2019, it was one of the fastest-growing generic injectables companies in the United States in terms of revenue. The company primarily sells its products under a brand name in various countries, including the United States, Europe, Canada, Australia, India, and the rest of the world.

The initial price target for Gland Pharma shares in 2025 is expected to be around ₹1800, and the second target price for Gland Pharma will be ₹2150.

MonthsGland Pharma Share Price Target 2025
January 2025Rs 1800
February 2025Rs 1810
March 2025Rs 1830
April 2025Rs 1850
May 2025Rs 1870
June 2025Rs 1900
July 2025Rs 1930
August 2025Rs 1970
September 2025Rs 2000
October 2025Rs 2040
November 2025Rs 2100
December 2025Rs 2150

Gland Pharma Share Price Target 2026

Gland Pharma has a consistent track record of complying with various regulatory frameworks in these markets. They possess extensive experience in the development, manufacturing, and marketing of complex injectable products, and have a strong understanding of the sophisticated scientific, technical, and regulatory processes involved. Established in 1978 in Hyderabad, India, the company has expanded from liquid parenterals to other elements of the injectable value chain, including contract development, in-house development, documentation preparation and filing, technology transfer, and manufacturing across a range of application systems.

The first share price target for Gland Pharma in 2026 is estimated to be ₹2200, while the second target could be approximately ₹2650.

MonthsGland Pharma Share Price Target 2026
January 2026Rs 2200
February 2026Rs 2230
March 2026Rs 2250
April 2026Rs 2270
May 2026Rs 2290
June 2026Rs 2340
July 2026Rs 2380
August 2026Rs 2450
September 2026Rs 2480
October 2026Rs 2540
November 2026Rs 2600
December 2026Rs 2650

Gland Pharma Share Price Target 2027

Gland Pharma has a professional management team, and one of its promoters, Shanghai Fosun Pharma, is a global pharmaceutical company. The company focuses on meeting diverse needs in the injectable sector with a steady supply of affordable and high-quality products. It has established a portfolio of injectable products across various therapeutic areas and application systems. Gland Pharma is present in sterile injectables, oncology, and ophthalmology, with a focus on complex injectable applications. Its delivery systems include liquid vials, lyophilized vials, prefilled syringes, ampoules, pouches, and drops.

The first share price target for Gland Pharma in 2027 is ₹2700, and the second target could exceed ₹3140.

MonthsGland Pharma Share Price Target 2027
January 2027Rs 2700
February 2027Rs 2750
March 2027Rs 2800
April 2027Rs 2840
May 2027Rs 2870
June 2027Rs 2920
July 2027Rs 2950
August 2027Rs 3000
September 2027Rs 3040
October 2027Rs 3070
November 2027Rs 3100
December 2027Rs 3140

Gland Pharma Share Price Target 2028

Gland Pharma has expanded its development and manufacturing capabilities to include complex injectables such as peptides, long-acting injectables, suspensions, and hormonal products, as well as new delivery systems like pens and cartridges. Gland Pharma, through its partner, has launched Bortezomib for Injection, 3.5 mg/vial, a single-dose vial, in the U.S. This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Velcade for Injection, 3.5 mg/vial, from Takeda Pharmaceuticals U.S.A., Inc. Bortezomib for Injection is used to treat certain types of cancer, such as multiple myeloma and mantle cell lymphoma.

The first share price target for Gland Pharma in 2028 is ₹3200, and the second target for FY 2028 is expected to be around ₹3700.

MonthsGland Pharma Share Price Target 2028
January 2028Rs 3200
February 2028Rs 3240
March 2028Rs 3280
April 2028Rs 3320
May 2028Rs 3350
June 2028Rs 3400
July 2028Rs 3450
August 2028Rs 3480
September 2028Rs 3530
October 2028Rs 3580
November 2028Rs 3640
December 2028Rs 3700
Gland Pharma Share Price Target

Gland Pharma Share Price Target 2030

Gland Pharma is engaged in complex injectables, contract development, and biosimilar manufacturing to accelerate short-term growth. The company has made significant progress in research and development regarding the planned launch of complex injectable doses scheduled for the current fiscal year. Gland Pharma is on track to complete four complex injectables this fiscal year. In the near future, the company is focusing on building a strong portfolio of complex injectable formulations. It is also looking at acquisition opportunities that will help accelerate its growth process. The setup for new lines for the administration of suspensions and hormonal preparations has been completed.

The first share price target for Gland Pharma in 2030 is expected to be ₹5200, and the second price target for Gland Pharma stock could reach ₹6000 by the end of FY 2030.

MonthsGland Pharma Share Price Target 2030
January 2030Rs 5200
February 2030Rs 5250
March 2030Rs 5300
April 2030Rs 5400
May 2030Rs 5450
June 2030Rs 5550
July 2030Rs 5600
August 2030Rs 5650
September 2030Rs 5700
October 2030Rs 5800
November 2030Rs 5900
December 2030Rs 6000

Future Prospectus of Gland Pharma Share

Gland Pharma is actively involved in complex injectables, contract development, and biosimilar manufacturing to accelerate short-term growth.

The company has expanded its development and manufacturing capabilities to include complex injectables such as peptides, long-acting injectables, suspensions, and hormonal products, as well as new delivery systems like pens and cartridges.

Gland Pharma Share F.A.Q.

Where is Gland Pharma’s headquarters located?

Gland Pharma’s headquarters is in Hyderabad.

Who is the current MD of Gland Pharma?

The current MD of Gland Pharma is from Shanghai Fosun.

What business does Gland Pharma engage in?

Gland Pharma is involved in the development, manufacturing, and sale of complex injectable formulations. The company primarily sells its products in various countries under a business-to-business model.

I hope that after reading the article on Gland Pharma Share Price Targets for 2025, 2026, 2027, 2028, and 2030, you now have a good idea of the potential performance of the company’s growth. If you still have any questions related to this article, don’t forget to mention them in the comments. For important information about stocks like this in the stock market, stay connected with Market in India.

Also read:-

Leave a Comment

Exit mobile version